chaetospirolactone

Chaetospirolactone is a **natural product** isolated from the endophytic fungus *Chaetomium* sp. NF00754. It has been studied primarily for its *antitumor properties* in preclinical models of pancreatic cancer, particularly for its ability to **reverse resistance to TRAIL** (tumor necrosis factor-related apoptosis-inducing ligand)-mediated apoptosis. Chaetospirolactone operates by upregulating **death receptor 4 (DR4)** on the surface of pancreatic cancer cells and repressing the enzyme **enhancer of zeste homolog 2 (EZH2)**, leading to reduced H3K27 trimethylation (H3K27me3), thus enabling increased DR4 transcription. As a result, it enhances susceptibility of TRAIL-resistant pancreatic cancer cells to apoptosis. Both in vitro and in vivo studies show that chaetospirolactone induces apoptosis in pancreatic cancer cells and, in combination with TRAIL, significantly suppresses tumor growth without notable toxicity[1][3][4][5].